BM 201

Drug Profile

BM 201

Alternative Names: BM201

Latest Information Update: 24 Jan 2017

Price : $50

At a glance

  • Originator BioMarin Pharmaceutical
  • Class Peptide hydrolases
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Burns

Most Recent Events

  • 23 Jan 2017 Discontinued - Preclinical for Burns in USA (unspecified route)
  • 31 Oct 2000 Suspended-Preclinical for Burns in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top